Provectus Biopharmaceuticals annual stock-based compensation
2002
2010
2011
2012
2013
2014
2015
2016
2018
2019
2020
2021
2022
2023
2024
2025
Provectus Biopharmaceuticals Stock-Based Compensation Growth & History (PVCT)
Provectus Biopharmaceuticals's stock-based compensation was $1.2M for fiscal 2025.
View full Provectus Biopharmaceuticals company overviewProvectus Biopharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.2M | −$43,230 | −3.38% |
| 2024 | 2024-12-31 | $1.3M | $1.3M | +44839.51% |
| 2023 | 2023-12-31 | $2,850 | −$175 | −5.79% |
| 2022 | 2022-12-31 | $3,025 | −$20,663 | −87.23% |
| 2021 | 2021-12-31 | $23,688 | −$111,066 | −82.42% |
| 2020 | 2020-12-31 | $134,754 | $111,775 | +486.42% |
| 2019 | 2019-12-31 | $22,979 | −$57,021 | −71.28% |
| 2018 | 2018-12-31 | $80,000 | — | — |
| 2016 | 2016-12-31 | $0 | −$670,576 | — |
| 2015 | 2015-12-31 | $670,576 | $554,931 | +479.86% |
| 2014 | 2014-12-31 | $115,645 | −$26,665 | −18.74% |
| 2013 | 2013-12-31 | $142,310 | −$40,718 | −22.25% |
| 2012 | 2012-12-31 | $183,028 | −$3.2M | −94.57% |
| 2011 | 2011-12-31 | $3.4M | −$390,700 | −10.39% |
| 2010 | 2010-12-31 | $3.8M | — | — |
| 2002 | 2002-12-31 | $932,000 | — | — |
Provectus Biopharmaceuticals quarterly stock-based compensation
Q2.11
Q3.11
Q2.12
Q3.12
Q3.13
Q3.14
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $305,944 | −$16,126 | −5.01% |
| Q1 2026 | 2026-03-31 | $306,051 | −$9,049 | −2.87% |
| Q4 2025 | 2025-12-31 | $287,601 | −$43,770 | −13.21% |
| Q3 2025 | 2025-09-30 | $312,775 | −$636,630 | −67.06% |
| Q2 2025 | 2025-06-30 | $322,070 | $322,070 | — |
| Q1 2025 | 2025-03-31 | $315,100 | $315,100 | — |
| Q4 2024 | 2024-12-31 | $331,371 | — | — |
| Q3 2024 | 2024-09-30 | $949,405 | — | — |
| Q2 2024 | 2024-06-30 | $0 | — | — |
| Q1 2024 | 2024-03-31 | $0 | — | — |
| Q4 2021 | 2021-12-31 | $0 | — | — |
| Q3 2021 | 2021-09-30 | $1,775 | −$1,903 | −51.74% |
| Q2 2021 | 2021-06-30 | $2,163 | — | — |
| Q1 2021 | 2021-03-31 | $19,750 | — | — |
| Q3 2020 | 2020-09-30 | $3,678 | $1,013 | +38.01% |
| Q4 2019 | 2019-12-31 | $1,239 | — | — |
| Q3 2019 | 2019-09-30 | $2,665 | $2,665 | — |
| Q2 2019 | 2019-06-30 | $16,425 | — | — |
| Q1 2019 | 2019-03-31 | $2,650 | — | — |
| Q3 2018 | 2018-09-30 | $0 | — | — |
| Q3 2014 | 2014-09-30 | $115,645 | −$26,665 | −18.74% |
| Q3 2013 | 2013-09-30 | $142,310 | $142,310 | — |
| Q3 2012 | 2012-09-30 | $0 | −$3.4M | — |
| Q2 2012 | 2012-06-30 | $183,028 | $183,028 | — |
| Q3 2011 | 2011-09-30 | $3.4M | — | — |
| Q2 2011 | 2011-06-30 | $0 | — | — |
Provectus Biopharmaceuticals stock-based compensation trends
Over the last five fiscal years, Provectus Biopharmaceuticals's stock-based compensation increased from $134,754 to $1.2M, a change of $1.1M. The latest reported quarter, Q2 2026, shows $305,944.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Provectus Biopharmaceuticals source filings ↗